Darzalex from Genmab A/ S - monoclonal antibody reshapes myeloma care

Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-29, 03:13. Details in the imprint.

The Darzalex brand from Genmab A/S sounds clinical on paper, but in an oncology ward it is the quiet drip that patients watch while clutching a blanket and listening to the soft beeping of infusion pumps. Nurses feel the cool glass vial in their hands and double-check the name before starting therapy.

How Darzalex works

Darzalex is a monoclonal antibody that targets the CD38 receptor on multiple myeloma cells, marking them for destruction by the patient’s immune system. It is used in combination with standard backbones such as lenalidomide, bortezomib or pomalidomide across several treatment lines.

In practical terms, Darzalex helps extend progression-free survival and deepen response rates, which means more time with stable disease and fewer symptoms for many patients. Oncologists describe it as a consistent building block in current myeloma combination regimens rather than a short-lived novelty.

From IV drip to subcutaneous shot

Originally, Darzalex entered the market as an intravenous infusion that could keep patients in the chair for several hours per cycle, especially during the first doses when infusion reactions had to be monitored closely. The routine involved premedication, a slow ramp-up of infusion rate and plenty of waiting.

Today, a subcutaneous formulation allows a much shorter administration time and a tidier workflow for ward staff, turning a long infusion visit into a relatively quick injection appointment for many regimens. Patients feel the sharp sting of the needle, but then they can leave far sooner than with the old drip-based schedule.

Where Darzalex fits in therapy

For newly diagnosed transplant-ineligible patients, Darzalex is often added to standard regimens to push response rates higher and delay progression. In transplant-eligible settings, it can be used as part of intensive induction or consolidation schemes tailored to individual risk profiles.

For relapsed and refractory myeloma, Darzalex combinations offer another line of defense after earlier treatments fail, which is crucial in a disease that tends to come back multiple times over a patient’s course. Physicians weigh prior therapies, cytogenetic risk and tolerance when deciding if and when to introduce Darzalex.

What patients and doctors notice

On the ward, hematologist Maria Jensen speaks of the "self-assured role" Darzalex plays in modern myeloma protocols, noting that colleagues now routinely reach for it when planning long-term management. She has seen frail patients who still manage day-to-day tasks thanks to added depth of response.

Patients often comment less on the drug name and more on the experience: the clinical smell of disinfectant wipes, the slightly raw feeling in the arm after subcutaneous injection and the relief of hearing that their protein markers have dropped again. For them, Darzalex is part of a broader journey rather than an isolated intervention.

Side effects and limitations

Darzalex can trigger infusion-related reactions, particularly with early doses, ranging from mild chills and cough to more serious symptoms that require intervention. Subcutaneous administration helps reduce some of this burden but monitoring remains standard practice.

Like other immunomodulating therapies, Darzalex can contribute to neutropenia and infections, so physicians track blood counts and adjust dosing or supportive care. The treatment does not cure multiple myeloma; instead it fits into a longer arc of managing a chronic, relapsing malignancy.

Commercial footprint and partnerships

Darzalex is commercialized globally through a partnership model, with Genmab providing the antibody technology and a large pharma partner handling much of the sales and marketing infrastructure. This structure allows broad reach into major oncology centers without Genmab fielding a full-scale salesforce.

From the business side, Darzalex contributes recurring royalty and milestone streams tied to sales volumes and label expansions, which matter for long-term cash flow. Every new indication or earlier-line use widens the real-world base of patients exposed to the brand.

Market access and pricing

Pricing for Darzalex can be substantial, reflecting the costs of biologic manufacturing and oncology drug development. Payers negotiate reimbursement based on clinical trial data and health-economic models that weigh progression-free survival against budget impact.

In practice, access varies by country and coverage system, with some markets offering broad reimbursement and others applying stricter criteria. Hospital pharmacists work within these frameworks to ensure that eligible patients can receive Darzalex without unexpected personal bills.

Stock context and listing

Overall, Darzalex exemplifies how Genmab’s antibody platform translates into a marketed product that shapes treatment decisions in a serious blood cancer while also underpinning recurring income for the company. Genmab shares (ISIN DK0010272202) are listed on Nasdaq Copenhagen in Danish kroner, giving investors direct exposure to this and other antibody programs.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.